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An efﬁcient strategy is presented for the identiﬁcation of antigenic sequences in the context of given MHC mol-
ecules of interest. The proteomic analysis of the antigenic peptide repertoire is described and demonstrated by
using high-molecular weight melanoma-associated antigen. The identiﬁcation of the epitopic sequence of a
monoclonal antibody raised against the 250 kDa tumor associated antigen was reached by using only seven short
synthetic peptide fragments, instead of the 155 non-overlapping 15-mer peptides theoretically necessary as min-
imum screening library. The present result has been obtained by applying as driving criteria the analysis of the
peptide afﬁnity to MHC class II molecules and the non-self discrimination concept.
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Tumor-associated antigens (TAA) are generally poorly
immunogenic due to mechanisms of immunotolerance: in-
deed, the majority of TAA are expressed in normal tissues at
low amounts. In this respect, the real challenge of cancer
immunotherapy is the scanning of disease-associated pro-
teins in the search for the specific antigenic determinants
evoking a vigorous immune response (Javia and Rosenb-
erg, 2003; Mukherjee et al, 2003; Pardoll, 2003).
The identification of antigenic peptide sequences, how-
ever, that promote immune responses against the full-length
antigen faces several problems. First, the diversity of pep-
tides deriving from the processing of an antigenic protein
with medium molecular weight (about 50 kDa) is enormous.
Second, the various T cell determinants and epitopes from a
single protein are not recognized with equal efficiency, and
there appears to be a hierarchy in the ability of any of these
epitopes to be recognized by T cells (Lehmann et al, 1993).
In addition, once a peptide has been screened and eval-
uated for binding potential to a MHC molecule and the
ability to be recognized by a T cell, there is no guarantee
that the peptide will induce anti-tumor antibodies. Actually,
immunogenicity is a quantity defined by higher-order reac-
tions (multivalent interactions, cell activation, activation of
the immune system, differential contributions of the various
factors, etc.) (Lehmann et al, 1993; Greenspan, 2001) and,
as such, affected by a variety of stochastic factors that
frame immune reactivity as a result of parameters defined
by localization, dose and time of antigens (Zinkernagel,
2000).
Finally, it is noteworthy to consider that, if a strong
humoral immune response is evoked, the possibility of side
effects in terms of autoimmune cross-reactions remains a
concrete risk (Engelhard et al, 2002; Turk et al, 2002).
The above-listed difficulties are increasingly emphasized
when high-molecular weight TAA are examined. Even con-
sidering a radically simplified recognition process dictated
by just the three spatial dimensions and a simplified level of
immunological activity, then, even in this abstract case, the
number of peptide sequences that have to be screened is
so extremely high to be practically preclusive only because
of economical considerations.
Here we study the high-molecular weight melanoma-as-
sociated-antigen (HMW-MAA) (Kantor et al, 1986; Pluschke
et al, 1996), a human membrane-bound protein often over-
expressed in melanoma and with restricted distribution in
normal tissue, and identify the epitopic sequence of this 250
kDa TAA as defined by the murine monoclonal antibody
(MAb) 225.28 (Imai et al, 1982; Giacomini et al, 1985; Kag-
eshita et al, 1993; Yang et al, 1993), using only seven short
synthetic peptides. This result has been obtained by utiliz-
ing proteomic database programs, and applying as driving
criteria the analysis of the peptide affinity to MHC class II
molecules and the non-self discrimination concept.
Results
Computational search for potentially epitopic HMW-
MAA sequences As a first step, the HMW-MAA was
analyzed for similarity to other proteins of the mouse pro-
teome. The protein sequence (amino acid 1–2322) was
Abbreviations: Fmoc, N-(9-fluorenyl)methoxycarbonyl; HMW-MAA,
high molecular weight melanoma-associated antigen; HPR, horse-
radish peroxidase; MAb, monoclonal antibody; MCSP, melanoma
chondroitin sulfate proteoglycan; PBST, PBS/0.05% (v/v) Tween-
20; PIR, Protein Information Resource; RT, room temperature; TAA,
tumor-associated antigen
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dissected into pentamers that were used as probes. The
pentamers were offset by one residue, i.e., overlapping by
four residues: i.e., MQSGR, QSGRG, SGRGP, GRGPP, etc.
The 5-mer sequences were probed in computer-assisted
similarity analyses by utilizing PIR non-redundant reference
protein database and peptide match program (Wu et al,
2002). The analysis put into evidence that a few stretches in
HMW-MAA protein have a low match number (or no match-
es at all) in common with the murine proteome, thus offering
possible epitopic determinants unknown to the host. As a
stringent selection criterium, HMW-MAA peptide fragments
with 0–10 total matches to the host’s proteome were arbi-
trarily considered as sequences of low similarity to be as-
sayed as potential epitopes.
As an additional selection criterium, we considered that
capability of peptide binding to MHC class II molecules is a
necessary prerequisite for T-helper cell recognition. There-
fore, in a second step, we searched for HMW-MAA 15-
mer peptides potentially able to bind H2-Ad/Ed molecules
by applying SYFPEITHY algorithm. Because of the high
number of possible 15-mer peptides from HMW-MAA, only
top-scoring MHC binding peptides were considered.
Usually, in the MHC-peptide interactions, the preferred
peptides have strong amino acid signals at certain key
positions called anchor, auxiliary anchor or preferred
residue. Rammensee et al (1999) have developed the
SYFPEITHI database of MHC ligands and peptide motifs
(http://www.uni-tuebingen.de/uni/kxi/) that calculates the
MHC binding potential score by giving the amino acids of
a certain peptide a specific value depending on whether
they are anchor, auxiliary anchor or preferred residue. Ami-
no acids that are regarded as having a negative effect on
the binding ability are also evaluated by a negative value.
The final score indicates the ligation strength, i.e., the pep-
tide’s probability of being bound and presented to the im-
mune system.
As a third step, the two lists of peptides were compared
in order to identify peptides of low similarity to self-proteins
and high binding potential to MHC class II molecules. Since
HMW-MAA protein might give rise to 2308 possible 15-mer
peptides, the search for low-similarity sequences was re-
stricted to the first 45 top-scoring 15-mer peptides as a
further selection criterium. The data obtained following the
analysis of the peptide similarity to the host proteome and
affinity to MHC class II molecules are illustrated in Table I
that reports the 15-mer peptide sequences harboring the
low-similarity HMW-MAA motifs and the relative binding
potential score to H2-Ad/Ed molecules. In Table I, also
the first two top-scoring HMW-MAA peptides for H2-Ad
and H2-Ed molecules are reported as binding score com-
parison. A first consideration is the extremely limited
number of sequences that were obtained. As a matter
of fact, numerous motifs having low-similarity such as
HMW-MAA421–433 LPPVFANFTQLLT (total number of
5-mer matches¼3), HMW-MAA473–483 TRGAHYGELEL
(total number of 5-mer matches¼2), HMW-MAA498–512
DVVNRKARFIHDGSE (total number of 5-mer matches¼3)
as well as even sequences having no counterpart at all
in the murine proteome such as HMW-MAA543–554
PIQVNPVNDPPH and HMW-MAA553–565 PHIIFPHGSLMVI
(each having a total number of 5-mer matches¼ 0), were
discarded by being not represented in any of the first 45
top-scoring MHC binding peptides.
The similarity pattern of the seven HMW-MAA fragments
elected for studying the antigenic determinant of the MAb
225.28 is described in Fig 1.
Table I. MHC II binding HMW-MAA 15-mer peptides hosting low-similarity motifs
MHC II Aa position Peptide sequencea Binding scoreb Similarity matchesc
H2-Ad 855 GRVTYGATARASEAVd 32 112
1440 LTDSFVLMANASEMDd 32 59
2251 KT GKHDVQVL TAKPRe 26 71
H2-Ed 1024 SRIFHVARGGRRLLTd 28 199
1078 IYRFTQEDLRKRRVLd 28 147
820 TFHYEVVQ APRKGNLe 26 77
942 L GRLAWRGTQ DKTTMe 20 63
300 VDQYPTHT SNRGVLSe 18 53
1417 LS AFSWRMVEEQ LIRe 18 72
1705 SHLWKNKG LWVPEGQe 18 46
2014 FTNFSS SHDHFRVL Ae 18 80
aPeptide sequences are provided using single-letter amino acid designations.
bMHC II binding score was obtained using SYFPEITHI program. Score is calculated by giving the amino acids of a certain peptide a specific value
depending on whether they are anchor, auxiliary anchor or preferred residue. The maximal score varies among different MHC alleles. The maximal score
possible is 34 for H2-Ad and H2-Ed. The search for low-similarity motifs was conducted among the first 45 top-scoring peptides.
cThe HMW-MAA 15-mer peptides were dissected into 5-mer probes and analyzed for similarity matches to mouse proteome as described under
Methods and Results. The total number of 5-mer matches is reported. The search was conducted against the mouse genome sequences reported in the
PIR database (77379 sequences).
dThe first two HMW-MAA 15-mer peptides, with top scoring binding values to H2-Ad and H2-Ed molecules respectively, are reported as binding score
comparisons.
eThe low-similarity peptide fragments selected for dot immunoassay analyses (see also Fig 1), are given bold.
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Glycosylation and proteolytic pattern of HMW-MAA pep-
tide sequences hosting low-similarity motifs The seven
selected low similarity HMW-MAA fragments described in
Fig 1 were further analyzed for glycosylation and proteolytic
sites as additional factors affecting peptide epitopicity. The
importance of intracellular antigen processing in the defini-
tion of antigenic determinants has been firmly established
(Sercarz et al, 1993), and cleavage at a single processing
site can be crucial for effective antigen presentation (Fines-
chi and Miller, 1997; Antoniou et al, 2000; Fruci et al, 2001;
Lemberg et al, 2001).
Moreover, it has to be noted that the anti-HMW-MAA
MAb 225.28 has been isolated from mice injected with hu-
man melanoma cells (Natali et al, 1985). That means that the
determinant recognized by the monoclonal antibody re-
flects the differential spatial distribution of antigen epitope
on the melanoma cell. Obviously, the epitope distribution is
biased by the conformation and post-translational modifi-
cations of the antigen in the melanoma cell. In this case, it is
influenced by the HMW-MAA post-translational modifica-
tions such as phosphorylation, glycosylation, folding, etc.
Indeed, treatment of melanoma cells with glycosidases dif-
ferentially affects their ability to bind anti-HMW-MAA mono-
clonal antibodies (Ziai et al, 1987).
Therefore, to reach a comprehensive better understand-
ing of the molecular basis of HMW-MAA peptide antigeni-
city, the glycosylation and predicted proteolytic patterns of
the selected HMW-MAA motifs were analyzed. The distri-
bution of proteolytic and glycosylation sites in the low-sim-
ilarity sequences is illustrated in Table II. The analysis was
extended to the first two 15-mer peptides with top-scoring
binding values to H2-Ad and H2-Ed molecules, respectively
Figure 1
Similarity scanning on the HMW-MAA peptide sequences selected
for immunoassay analysis with MAb 225.28. Matching analysis to the
mouse proteome was performed using as probes pentamers offset by
one residue as described under Materials and Methods.
Table II. Glycosylation and predicted proteolytic pattern of
potentially antigenic HMW-MAA peptides
Peptidea
Aa
position Sequenceb
Similarity
matchesc
C1 855–869 |GRVT|YGA|TA|RASE|A|V| 112
C2 1024–1038 SR|I|FHVAR|GGR|RLL|T 199
C3 1078–1092 IYRFTQ|EDL|RKR|RVL 147
C4 1440–1454 L|TDSFV|L|MA|NA|SEM|D| 59
1 300–307 VD|QY|PTHT| 4
2 820–828 TF|H|Y|E|V|V|Q|A| 2
3 943–951 GR|LAWRGTQ| 10
4 1419–1428 AF|S|WRMVE|E|Q 5
5 1705–1712 SHLWKNK|G 8
6 2020–2027 S|H|DH|FRV|Ld 5
7 2253–2260 GKH|D|V|QV|L|d 8
aC1–C4 peptides refer to the the first two H2-A
d/Ed high-affinity 15-mer
peptides described in Table I. The low-similarity peptide motifs are
numbered 1–7 as described in Fig 1.
bGlycosylation sites (NXS/T) are underlined. Proteolytic sites were
analyzed by PAProc mammalian wild type I program (17) and are
indicated by vertical lines (|).
cSimilarity level is expressed as match number. The total number of 5-
mer matches is reported. Similarity analysis was conducted against the
mouse genome sequences reported in the PIR database (77379
sequences) as described under Materials and Methods.
dGlycosylation sites are present in the flanking NH2 and COOH regions.
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(i.e., the HMW-MAA855–869 GRVTYGATARASEAV and HMW-
MAA1440–1454 LTDSFVLMANASEMD sequences for H2-A
d;
the HMW-MAA1024–1038 SRIFHVARGGRRLLT and HMW-
MAA1078–1092 IYRFTQEDLRKRRVL sequences for H2-E
d).
These high-affinity 15-mer sequences were enclosed in or-
der to be used as peptide controls in the dot-blot immuno-
assays.
Identiﬁcation of the MAb 225.28 linear antigenic deter-
minant Following the analyses and screening described
above, the selected low-similarity HMW-MAA sequences
illustrated in Fig 1 were examined as potential epitopic de-
terminants of the MAb 225.28. To this aim, the correspond-
ing peptides were synthesized and used as antigenic
fragments in dot-blot immunoassays with the MAb
225.28. In addition, independent of their similarity level,
the first two 15-mer peptides with top-scoring binding
values to H2-Ad and H2-Ed molecules, respectively (i.e.,
the HMW-MAA855–869 GRVTYGATARASEAV and HMW-
MAA1440–1454 LTDSFVLMANASEMD sequences for H2-A
d,
the HMW-MAA1024–1038 SRIFHVARGGRRLLT and HMW-
MAA1078–1092 IYRFTQEDLRKRRVL sequences for H2-E
d, as
reported in Table I) were synthetized and enclosed as pep-
tide controls to better define the contribution of MHC II af-
finity to peptide epitopicity.
Figure 2, panel A, documents that, among the poten-
tial epitopic motifs, the synthetic HMW-MAA1705–1712
SHLWKNKG peptide sharing eight matches with mouse
proteome and hosted by a 15-mer peptide able to bind to
H2-Ed molecules with a relatively low affinity (score¼18),
was recognized by the anti-HMW-MAA MAb 225.28 (Fig 2,
panel A, peptide no. 5). The specificity of the immune
reaction between HMW-MAA1705–1712 SHLWKNKG peptide
and MAb 225.28 is further illustrated in Fig 2, panel B, that
shows the dependence of the chemiluminescence signal
intensity on the concentration of the epitopic peptide.
Moreover, Western blotting analysis of human Colo38 cells,
which are known to express HMW-MAA antigen (Giacomini
et al, 1985), revealed that reactivity of MAb 225.28 with
high-molecular band was inhibited by pre-treatment with
the epitopic HMW-MAA1705–1712 SHLWKNKG peptide, but
not by HMW-MAA1419–1428 AFSWRMVEEQ peptide (Fig 2,
panel C).
Moreover, analysis of Fig 2 put into evidence that the
epitope HMW-MAA1705–1712 SHLWKNKG peptide (peptide
no. 5 in Fig 2) is hosted in a peptide sequence (i) free of
internal/flanking glycosylation sites (NXS/T) and (ii) with the
lowest number of proteolytic sites, e.g., is less susceptible
to proteolytic fragmentation.
Discussion
The present HMW-MAA epitope identification (i) validates
an approach we already used for identifying the linear an-
tigenic determinant of monoclonal antibodies raised against
Figure 2
Identification of HMW-MAA1705–1712 SHLWKNKG as epitopic peptide sequence recognized by the MAb225.28. (Panel A) Immunoreactivity of
low-similarity HMW-MAA motifs with MAb 225.28 was analyzed by dot-blot immunoassay as described under Materials and Methods, using a MAb
raised against the Melan-A/MART-1 oncoprotein (MAb-1) as control. Control peptides C1–C4 correspond, in that order, to HMW-MAA855–869
GRVTYGATARASEAV, HMW-MAA1024–1038 SRIFHVARGGRRLLT, HMW-MAA1440–1454 LTDSFVLMANASEMD, HMW-MAA1078–1092 IYRFT-
QEDLRKRRVL peptides as described in Table II. Low-similarity peptides from 1 to 7 correspond, in that order, to HMW-MAA300–307 VDQYPTHT,
HMW-MAA820–828 TFHYEVVQA, HMW-MAA943–951 GRLAWRGTQ, HMW-MAA1419–1428 AFSWRMVEEQ, HMW-MAA1705–1712 SHLWKNKG, HMW-
MAA2020–2027 SHDHFRVL, HMW-MAA2253–2260 GKHDVQVL, as described in Fig 1. MHC II binding score, similarity level, glycosylation, and pro-
teolytic sites were defined and analyzed as detailed under Materials and Methods and in the legend to Fig 1 and Table II. MHC II binding score
values of peptides 1–7 refer to the 15-mer sequence hosting the low-similarity fragment (see Table I). Asterisk indicates flanking glycosylation sites.
(Panel B) HMW-MAA1705–1712 SHLWKNKG peptide titration dot-blot assay was performed as described under Materials and Methods using 0.25 mg
MAb 225.28 in 2.5 mL PBST/4% BSA. Peptide: C1, HMW-MAA855–869 GRVTYGATARASEAV; 4, HMW-MAA1419–1428 AFSWRMVEEQ; 5, HMW-
MAA1705–1712 SHLWKNKG. (Panel C) Immunoblotting of human HMW-MAA by MAb 225.28, and inhibition analysis by HMW-MAA1705–1712
SHLWKNKG were carried out using negative control B lymphoid L14 (lane 1) and melanoma Colo38 cell lysate (lane 2). Cell lysates were resolved on
SDS-10% PAGE and the immunoblot membrane probed with MAb 225.28 alone, or plus HMW-MAA1419–1428 AFSWRMVEEQ (peptide no. 4) or
HMW-MAA1705-1712 SHLWKNKG (peptide no. 5). On the left, molecular mass marker in kDa.
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the viral HPV16 E7 oncoprotein, breast-cancer-associated
HER-2/neu oncoprotein, the Pemphigus vulgaris associated
Dsg3 autoantigen (Kanduc et al, 2001a; Kanduc et al,
2001b; Mittelman et al, 2002; Lucchese et al, 2003; Dummer
et al, 2004), the gastro-intestinal cancer associated CEA,
the prostate specific antigen (PSA), the melanoma-associ-
ated antigen tyrosinase, the melanoma-associated antigen
Melan-A/MART-1 (manuscripts submitted/in preparation);
(ii) deals with a protein, e.g., HMW-MAA, whose large di-
mension (amino acids 1–2322) has by itself prevented pre-
cisly defined epitope mapping till now; and (iii) opens a new
avenue to effective anti-melanoma vaccine formulations
devoid of side-effects.
Indeed, in the antigenic multiplicity that characterizes
melanoma cells, HMW-MAA is an important target for
immunotherapy since it has a high density on melanoma
cells, is expressed on metastatic lesions and has a limited
distribution in normal tissues (Ferrone et al, 1993). On the
other hand, the development of anti-HMW-MAA immunity
has been obstacled by the difficulty of exactly mapping the
potential epitopic motifs of this melanoma antigen. Accord-
ingly, phage-displayed random-peptide libraries have been
developed to search for epitopic peptide mimics of mono-
clonal antibodies, in the hope that the identification of
the neutralizing epitopes of anti-melanoma antibodies may
provide information for the design of effective vaccine. The
use of peptide mimics of the human tumor associated an-
tigen also has the valence of fighting the tumor escape
from immunosurveillance: most of the TAA used for
specific immunotherapy are self-antigens and impose the
development of strategies effective in breaking tolerance to
the self.
In the present case, preliminarly we have to underscore that
our data define the epitopicity of the HMW-MAA1705–1712
SHLWKNKG peptide, but do not give any information
about its immunogenicity. We still need to demonstrate that
the HMW-MAA1705–1712 SHLWKNKG peptide is able to in-
duce a specific immune response in vivo. Given this caveat,
it has to be noted that antigenic low-similarity epitopes also
having the capability to evoke an immune response, might
be potentially important for a possible therapeutic approach.
In fact, the application of non-self discrimination to the
identification of immunogenic peptides would offer the con-
crete possibility of vigorous (i.e., without the attenuation due
to the self-tolerance) and safe (i.e., devoid of side autoim-
mune effects) immunotherapies. Indeed, the lines drawn in
the continuum of immune activity, from inactivity, tolerance,
low reactivity to aggressive reaction are feeble and the di-
lemma between vaccination and autoimmunity is well known
(Nossal, 2000; Gilboa, 2001). In particular, as regards the
melanoma chondroitin sulfate proteoglycan studied here, it
has been ascertained that experimental immunity to the
proteoglycan versican induces spondylitis and sacroiliitis, of
a kind seen in human spondylarthropathies (Shi et al, 2003).
Consequently, the use of melanoma chondroitin sulfate pro-
teoglycan peptides with demonstrated immunogenic poten-
tial and no similarity counterpart in the host proteome would
minimize the possibility of autoreactivity in possible anti-
melanoma immunotherapeutic approaches.
Moreover, the here-reported three-steps, proteomics–
based identification of HMW-MAA epitope appears impor-
tant since it demonstrates that the logical application of
algorithms makes the identification of antigenic epitopes a
reachable goal even in the case of proteins having high-
molecular weight. As a matter of fact, the methodology
used in this study was extremely effective for identifying one
epitopic site in a complex protein, a result that would have
not been achieved by a canonical peptide-mapping anal-
ysis. A library of non-overlapping 155 peptides, each 15
residues in length and covering the entire sequence of
HMW-MAA, should have been screened. So, compared
with other methods for epitope mapping, derivation of these
ligands was rapid and inexpensive.
Finally, the preliminary analysis reported in Table II sug-
gests that application of the present approach to the com-
parative screening of potential epitopes by MAbs raised
against whole cells and recombinant pure proteins, might
clear the molecular basis of peptide immunoreactivity in
relationship to the post-translational modification pattern of
the antigen.
Materials and Methods
Computational analyses The analyzed human HMW-MAA (or
MCSP, melanoma chondroitin sulfate proteoglycan) sequence
(GenBank Accession No: AAQ62842) was as reported in Pluschke
et al, 1996. Sequence similarity analyses to mouse proteins were
conducted by using PIR sequence analysis programs (http://
pir.georgetown.edu/pirwww) (Wu et al, 2002). SYFPEITHI program
(http://www.uni-tuebingen.de/uni/kxi/) (Rammensee et al, 1999)
was used as a database of MHC ligands and peptide motifs in the
calculation of peptide binding potential to MHC class II molecules.
The HMW-MAA proteolytic pattern was analyzed by Prediction
Algorithm for Proteasomal Cleavages (PAProc, http://www.uni-
tuebingen.de/uni/kxi/) (Kuttler et al, 2000).
Peptides and antibodies The following synthetic peptides were
used in dot-blot immunoassays: HMW-MAA300–307 VDQYPTHT,
HMW-MAA820–828 TFHYEVVQA, HMW-MAA855–869 GRVTYGA-
TARASEAV, HMW-MAA943–951 GRLAWRGTQ, HMW-MAA1024–1038
SRIFHVARGGRRLLT, HMW-MAA1078–1092 IYRFTQEDLRKRRVL,
HMW-MAA1419–1428 AFSWRMVEEQ, HMW-MAA1440–1454 LTD-
SFVLMANASEMD, HMW-MAA1705–1712 SHLWKNKG, HMW-
MAA2020–2027 SHDHFRVL, HMW-MAA2253–2260 GKHDVQVL. Pep-
tides were synthesized by standard Fmoc (N-(9-fluorenyl)methoxy-
carbonyl) solid phase peptide synthesis (Primm srl, Milan, Italy).
The purity of the peptides was greater than 95% as assessed by
high-performance liquid chromatography, and the molecular mass
of purified peptides was confirmed by fast-atom bombardment
mass spectrometry. Peptides were dissolved in 0.9% NaCl, ali-
quoted and stored at 201C.
Primary antibody was a mouse monoclonal antibody (MAb
225.28), elicited with human melanoma cells and reacting with a
specific determinant of the HMW-MAA (Imai et al, 1982; Giacomini
et al, 1985; Kageshita et al, 1993; Yang et al, 1993). Anti Melan-A/
MART-1 MAb (MAb-1 from clone M2-7C10, Labvision, Neomark-
ers, Fremont, California) was used as control. HRP-conjugated af-
finity-purified anti-mouse IgGs (Sigma-Aldrich srl, Milan, Italy) were
used as secondary antibodies.
Dot-blot and western blot immunoassay In dot-blot assays, ni-
trocellulose membrane (0.2 mm pore size, BioRad Laboratories,
Milan, Italy) was pre-treated for 10 min with 2.5% glutaraldehyde.
Peptides (4 mg, or otherwise stated) were spotted on the activated
membranes and left to dry at room temperature. To block non-
specific binding sites, membranes were incubated for 1 h in phos-
phate-buffered saline/0.05% (v/v) Tween-20 (PBST) containing 4%
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bovine serum albumin (BSA) and then with the primary antibody
(1:800). Following 1 h incubation at RT, membranes were washed for
10 min with PBST (3) and further incubated in PBST/4% BSA for
1h with secondary antibodies (1:5000). Membranes were washed in
PBST for 5 min (3), in PBS for 5 min (3), and immunoblots were
developed using the enhanced chemiluminescence detection assay
(ECL analysis system, Amersham Biotech, Milan, Italy).
Human melanoma Colo38 and human B lymphoid L14 cell
lysates (35 mg) were resolved on sodium dodecylsulfate-10%
polyacrylamide gel-electrophoresis (SDS-PAGE). Following SDS-
PAGE, the proteins were electroblotted overnight onto poly-
vinylidene difluoride membrane (0.45 mm pore size, BioRad). The
membrane was blocked with PBST/4% BSA, and then probed with
MAb 225.28 (10 mg per mL PBST/4% BSA) or with MAb 225.28
plus HMW-MAA1705–1712 SHLWKNKG peptide or with MAb 225.28
plus HMW-MAA1419–1428 AFSWRMVEEQ peptide (peptide:MAb,
0.1:1, mg per mg). Following incubation with HRP-conjugated anti-
mouse IgGs (Sigma-Aldrich), immunoblots were developed using
the enhanced chemiluminescence detection assay (Amersham
Pharmacia Biotech).
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